CN116096747A - 免疫原性降低型低分子抗体及其制造法 - Google Patents

免疫原性降低型低分子抗体及其制造法 Download PDF

Info

Publication number
CN116096747A
CN116096747A CN202180056535.9A CN202180056535A CN116096747A CN 116096747 A CN116096747 A CN 116096747A CN 202180056535 A CN202180056535 A CN 202180056535A CN 116096747 A CN116096747 A CN 116096747A
Authority
CN
China
Prior art keywords
ser
gly
ala
val
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180056535.9A
Other languages
English (en)
Chinese (zh)
Inventor
野中元裕
大石真也
大野浩章
青木启辅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyoto University NUC
Original Assignee
Kyoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyoto University NUC filed Critical Kyoto University NUC
Publication of CN116096747A publication Critical patent/CN116096747A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
CN202180056535.9A 2020-06-18 2021-06-17 免疫原性降低型低分子抗体及其制造法 Pending CN116096747A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-105104 2020-06-18
JP2020105104 2020-06-18
PCT/JP2021/022968 WO2021256524A1 (ja) 2020-06-18 2021-06-17 免疫原性低減型低分子抗体とその製造法

Publications (1)

Publication Number Publication Date
CN116096747A true CN116096747A (zh) 2023-05-09

Family

ID=79268044

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180056535.9A Pending CN116096747A (zh) 2020-06-18 2021-06-17 免疫原性降低型低分子抗体及其制造法

Country Status (5)

Country Link
US (1) US20230227536A1 (https=)
EP (1) EP4169940A1 (https=)
JP (1) JPWO2021256524A1 (https=)
CN (1) CN116096747A (https=)
WO (1) WO2021256524A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3244280A1 (en) 2022-02-17 2023-08-24 Rules-Based Medicine Inc. SINGLE-DOMAIN ANTIBODY BANK WITH MAXIMIZED ANTIBODY DEVELOPMENT CHARACTERISTICS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014207321A1 (en) * 2013-01-21 2015-07-23 Abbvie Inc. Anti-TNF and anti-IL17 combination therapy biomarkers for inflammatory disease
US20170107541A1 (en) * 2014-06-17 2017-04-20 Poseida Therapeutics, Inc. A method for directing proteins to specific loci in the genome and uses thereof
JP7224585B2 (ja) 2018-12-27 2023-02-20 山田化学工業株式会社 フォトクロミック化合物

Also Published As

Publication number Publication date
WO2021256524A1 (ja) 2021-12-23
EP4169940A1 (en) 2023-04-26
US20230227536A1 (en) 2023-07-20
JPWO2021256524A1 (https=) 2021-12-23

Similar Documents

Publication Publication Date Title
JP2020186248A5 (https=)
JP6165713B2 (ja) インスリン様増殖因子１に特異的に結合する抗体
JP2022023181A (ja) Ｃ末端リジンで結合体化された免疫グロブリン
CN105555310B (zh) 一种提高蛋白血清半衰期的组合物和方法
JP6943764B2 (ja) Ｉｌ−１７ａ結合ポリペプチド
CN107614514A (zh) 利用IgG结合肽的抗体特异性修饰
JP2005535301A5 (https=)
WO2014103203A1 (ja) 微小タンパク質の骨格構造に基づく分子ライブラリ
CN106488930B (zh) 新型多肽
CN116096747A (zh) 免疫原性降低型低分子抗体及其制造法
CN110475779A (zh) 标记含醛靶分子的方法
EP4126046A1 (en) Anti-gipr antibody and methods of use thereof
CN120209142A (zh) 一种靶向Ly6G6D的纳米抗体及其应用
JP7853222B2 (ja) 合成単一ドメインライブラリー
AU2023357539A1 (en) Ultrastable antibody fragments with a novel disuldide bridge
JP2017014112A (ja) 抗サバイビン抗体又は抗体誘導体及びそれらの利用
CN120659804A (zh) 多价蛋白质及筛选方法
JP2017043625A (ja) Ｖｅｇｆ結合性ペプチド
JP2026505450A (ja) 一本鎖抗体断片の化学合成法およびそれにより得られる物
Aoki Development of Mirror-Image VHHs with Less Immunogenicity
Aoki Chemical Synthesis of Mirror-Image VHHs and Evaluation of Their Immunogenicity
CA3268444A1 (en) Ultrastable antibody fragments with a novel disuldide bridge
CN114846030A (zh) 催化抗体38c2的新型缀合化学
KR20260025152A (ko) 접합된 분자
WO2025223473A1 (zh) 抗gdf-15抗体及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination